​STUDY REVEALS GLUTATHIONE'S ROLE IN COMBATING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

TOKYO, May 6 (Bernama-BUSINESS WIRE) -- The results of a recent multi-center clinical study show, for the first time, that oral administration of KOHJIN Glutathione (L-Glutathione Reduced, GSH) is effective against the onset and progress of NAFLD, and metabolic syndrome in the broader view. The implications of this study, which was presented at the International Liver Congress 2016 in Barcelona, Spain, are unprecedented as, to date, no available drug therapy had been shown effective in the treatment of NAFLD (ILC 2016 #FRI-340).
 
NAFLD, which can progress to nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma, is a rising worldwide threat, particularly in the United States, where the morbidity rate has soared as high as 30%. The study looks at 34 subjects who were administered 300 mg daily of Glutathione over a period of four months, and concludes with a comparison of both clinical parameters and image-view observation of steatosis (adipose degeneration), with the aid of transient elastography, according to each subject’s detailed profile before and after treatment with Glutathione. The improvement in physical condition along both lines was decisive. Alanine aminotransferase (ALT) and Controlled attenuation parameter (CAP/Fibroscan) levels were significantly lowered.

http://mrem.bernama.com/viewsm.php?idm=26743